Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 1, 2013, Pages 23-27

  Hagiwara, M ^a   Delea, T E ^a   Saville, M W ^b   Chung, K ^b  

^a POLICY ANALYSIS INC PAI   (United States)

^b AMGEN INC   (United States)

Author keywords

healthcare costs; metastases; prostatic neoplasms; skeletal related events

Indexed keywords

ADULT; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ORTHOPEDIC SURGERY; OUTPATIENT; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SPINAL CORD DECOMPRESSION;

BONE NEOPLASMS; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84873708242     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.42     Document Type: Article

References (29)

1. American Cancer Society. Detailed guide: prostate cancer what are the key statistics about prostate cancer? Available at http://www.cancer.org/Cancer/ Prostate Cancer/DetailedGuide/prostate-cancer-key-statistics. Accessed 31 January 2012.
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80(8 Suppl): 1588-1594. (Pubitemid 27444031)
3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593. (Pubitemid 37328925)
4. Ohmori K, Matsui H, Yasuda T, Kanamori M, Yudoh K, Seto H et al. Evaluation of the prognosis of cancer patients with metastatic bone tumors based on serial bone scintigrams. Jpn J Clin Oncol 1997; 27: 263-267. (Pubitemid 127516777)
5. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202. (Pubitemid 18023133)
6. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
7. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176. (Pubitemid 32452017)
8. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-1007.
9. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Longterm efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882. (Pubitemid 38807610)
10. Barlev A, Song X, Ivanov B, Setty V, Chung K. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010; 16: 693-702.
11. Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004; 67: 390-396.
12. Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006; 4: 341-347. (Pubitemid 44420137)
13. Delea TE, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006; 1: 571-576. (Pubitemid 47181406)
14. Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008; 14: 317-322.
15. Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol 2007; 178(4 Pt 1): 1423-1428. (Pubitemid 47376713)
16. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003; 43: 226-232. (Pubitemid 36314233)
17. McKiernan JM, Delea TE, Brandman J, Sung J, Raut M, Oster G. Effects of skeletal complications on total medical care costs in patients with bone metastases of solid tumors. American Society of Clinical Oncology 41st Annual Meeting, May 15, 2005 Orlando, FL (Poster). J Clin Oncol 2004 ASCO Annual Meeting Proceedings 2004; 22: 6057.
18. Hagiwara M, Oglesby A, Chung K, Zilber S, Delea TE. The impact of bone metastases and skeletal-related events on healthcare costs in prostate cancer patients receiving hormonal therapy. Community Oncol 2011; 8: 508-515.
19. Hornbrook MC, Hurtado AV, Johnson RE. Health care episodes: definition, measurement and use. Med Care Rev 1985; 42: 163-218.
20. Mehta SS, Suzuki S, Glick HA, Schulman KA. Determining an episode of care using claims data. Diabetic foot ulcer. Diabetes Care 1999; 22: 1110-1115. (Pubitemid 29293964)
21. Klinkman MS. Episodes of care for abdominal pain in a primary care practice. Arch Fam Med 1996; 5: 279-285. (Pubitemid 126445113)
22. Shekelle PG, Markovich M, Louie R. Comparing the costs between provider types of episodes of back pain care. Spine (Phila Pa 1976) 1995; 20: 221-226; discussion 227.
23. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
24. Abrahm JL, Banffy MB, Harris MB. Spinal cord compression in patients with advanced metastatic cancer: 'all I care about is walking and living my life'. JAMA 2008; 299: 937-946. (Pubitemid 351397067)
25. Conway R, Graham J, Kidd J, Levack P. What happens to people after malignant cord compression? Survival, function, quality of life, emotional well-being and place of care 1 month after diagnosis. Clin Oncol (R Coll Radiol) 2007; 19: 56-62. (Pubitemid 46044073)
26. Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 2005; 23: 2028-2037. (Pubitemid 46211383)
27. Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. J Clin Oncol 1998; 16: 1613-1624. (Pubitemid 28175788)
28. Bureau of Labor Statistics. Consumer Price Index. Medical Care, US City Average. Series Id: CUUR0000SAM, CUUS0000SAM. US Department of Labor: Washington, DC, 2008, Available fromURL http://www.bls.gov/cpi/home.htm.
29. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.